STOCK TITAN

Reviva Pharma Holdings (RVPH) Form 4 Filings

RVPH OTC

Here are the Form 4 insider transactions from Reviva Pharma Holdings Inc (RVPH) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A Form 4 covers the transactions officers, directors and large holders report, so if you follow RVPH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RVPH filings page.

Rhea-AI Summary

REVIVA PHARMACEUTICALS HOLDINGS, INC. Chief Financial Officer Prabhu Narayan received a grant of stock options covering 40,925 shares of common stock on the grant date of March 18, 2026. These options have an exercise price of $1.87 per share and expire on March 17, 2036.

The award vests over time under the company’s 2020 Equity Incentive Plan. Of the total, 12,789 option shares vested immediately on the grant date, while the remaining 28,136 shares will vest in equal monthly installments from April 2026 through December 2028, encouraging long-term alignment with the company.

Rhea-AI Summary

REVIVA PHARMACEUTICALS HOLDINGS, INC. President and CEO Laxminarayan Bhat reported receiving two stock option awards under the company’s 2020 Equity Incentive Plan. The grants cover a total of 150,075 options to buy common stock at an exercise price of $1.87 per share, expiring on March 17, 2036.

One option for 109,150 shares is held directly and another for 40,925 shares is held indirectly through his spouse. For the direct grant, 34,110 options vest immediately and 75,040 vest in equal monthly installments from April 2026 to December 2028. For the spouse-held grant, 12,789 options vest immediately and 28,136 vest on the same monthly schedule. These are compensation-related awards, not open‑market share purchases or sales.